Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on July 9, 2018. The registrant is incorporated in California and is designated as an emerging growth company. The filing serves primarily to disclose a press release issued on the same date under Regulation FD (Item 7.01).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a press release rather than a financial statement report.
Material Changes
No material financial changes or comparative period data are detailed within the text of this Form 8-K. The report references a press release (Exhibit 99.1) for specific details but does not summarize the content of that release.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks.
- Risk Factors: Specific risks are not listed in this text; investors are directed to the "Risk Factors" section of the company's most recent Form 10-K and Form 10-Q.
- Unusual Items: No unusual items are described in the body of this report.
Key Facts for Investor Verification
- Verify the content of the press release dated July 9, 2018, which is attached as Exhibit 99.1, as the 8-K itself contains no operational details.
- Confirm the company name is OncoCyte Corporation, as the input metadata referenced a different entity name.
- Review the most recent Form 10-K and 10-Q for detailed financial metrics and risk factors, as this 8-K does not contain them.
- Note that the registrant is an emerging growth company, which may affect financial reporting standards.